Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gastrointestinal sensory nerve endings are specialized neuronal structures located throughout the layers of the gastrointestinal (GI) tract, originating from both extrinsic (vagal and spinal afferents) and intrinsic (enteric) neurons[1][4][6]. These endings are not a single molecule or protein, but rather the terminal axonal arborizations of sensory (afferent) neurons. Their function is to detect changes in the gut environment—such as mechanical stretch, chemical composition, and noxious stimuli—and relay this information to either the central nervous system (via spinal and vagal pathways) or to local enteric circuits, thereby modulating digestive processes like motility, secretion, and local immune responses[1][6][7]. Gastrointestinal sensory nerve endings include distinct morphological and neurochemical subtypes, such as those positive for the neuropeptide CGRP, and are found innervating multiple gut layers (submucosa, muscle, mucosa, vasculature)[4][6]. Key functional classes of afferents include mechanoreceptors, chemoreceptors, and thermoreceptors, each detecting different stimuli in the GI tract[2]. Intrinsic sensory endings, called intrinsic primary afferent neurons (IPANs), form part of the enteric nervous system and coordinate local reflexes independently of the central nervous system, but do not transmit conscious sensations to the brain[1][6]. Notably, "gastrointestinal sensory nerve ending" is not a canonical drug target in the sense of a defined molecular entity such as a receptor, enzyme, or channel; rather, it is an anatomical concept referring to where sensory axons terminate in the gut. Actual therapeutic targets are often ion channels (e.g., TRPA1, Piezo2), neuropeptide receptors (e.g., CGRP receptor, CCK receptor), or proteins expressed by these afferents[6]. Due to this, the term is too broad and not specific enough for use as a canonical therapeutic target. The relevant drug targets are the molecular entities (receptors, ion channels) present on the endings themselves. --- - This entry is not a standard molecular target; it represents anatomical and cellular structures composed of heterogeneous proteins and cell types, not a single defined molecule[1][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gastrointestinal sensory nerve ending.